State of New Jersey Common Pension Fund D Has $4.42 Million Stock Holdings in Exelixis, Inc. (NASDAQ:EXEL)

State of New Jersey Common Pension Fund D increased its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 8.6% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 184,279 shares of the biotechnology company’s stock after acquiring an additional 14,517 shares during the period. State of New Jersey Common Pension Fund D owned about 0.06% of Exelixis worth $4,421,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. CWM LLC raised its holdings in Exelixis by 17.3% in the third quarter. CWM LLC now owns 7,698 shares of the biotechnology company’s stock worth $168,000 after purchasing an additional 1,136 shares during the period. SG Americas Securities LLC acquired a new position in shares of Exelixis during the 3rd quarter worth about $1,742,000. Ballentine Partners LLC bought a new stake in Exelixis in the third quarter valued at approximately $301,000. Denali Advisors LLC lifted its holdings in Exelixis by 7,995.2% during the 3rd quarter. Denali Advisors LLC now owns 1,700 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 1,679 shares during the last quarter. Finally, Commonwealth Equity Services LLC raised its holdings in Exelixis by 4.0% in the 3rd quarter. Commonwealth Equity Services LLC now owns 120,479 shares of the biotechnology company’s stock valued at $2,632,000 after acquiring an additional 4,639 shares during the period. 85.27% of the stock is currently owned by institutional investors.

Exelixis Stock Performance

Shares of EXEL stock traded up $0.17 during mid-day trading on Friday, hitting $23.70. 1,560,646 shares of the stock were exchanged, compared to its average volume of 2,255,847. Exelixis, Inc. has a 12-month low of $18.08 and a 12-month high of $24.34. The stock has a market capitalization of $6.99 billion, a price-to-earnings ratio of 37.03, a P/E/G ratio of 0.63 and a beta of 0.54. The stock’s fifty day simple moving average is $22.80 and its two-hundred day simple moving average is $22.18.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings results on Tuesday, February 6th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.02. Exelixis had a return on equity of 8.57% and a net margin of 11.35%. The firm had revenue of $479.65 million for the quarter, compared to analysts’ expectations of $481.23 million. On average, research analysts expect that Exelixis, Inc. will post 1.21 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on EXEL shares. JMP Securities restated a “market outperform” rating and issued a $27.00 price target on shares of Exelixis in a research note on Wednesday, April 10th. TheStreet upgraded Exelixis from a “c+” rating to a “b-” rating in a research note on Monday, March 18th. Royal Bank of Canada raised their target price on Exelixis from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 7th. Barclays downgraded Exelixis from an “overweight” rating to an “equal weight” rating and set a $25.00 target price for the company. in a research note on Thursday, April 11th. Finally, William Blair reaffirmed an “outperform” rating on shares of Exelixis in a report on Friday, January 26th. Six investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $26.29.

Insider Buying and Selling at Exelixis

In other news, Director Alan M. Garber sold 19,205 shares of Exelixis stock in a transaction dated Thursday, March 21st. The stock was sold at an average price of $24.01, for a total value of $461,112.05. Following the transaction, the director now directly owns 35,703 shares of the company’s stock, valued at approximately $857,229.03. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Exelixis news, Director Alan M. Garber sold 19,205 shares of the stock in a transaction on Thursday, March 21st. The stock was sold at an average price of $24.01, for a total transaction of $461,112.05. Following the completion of the transaction, the director now directly owns 35,703 shares of the company’s stock, valued at approximately $857,229.03. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director David Edward Johnson bought 190,000 shares of Exelixis stock in a transaction that occurred on Wednesday, February 21st. The shares were acquired at an average price of $20.70 per share, with a total value of $3,933,000.00. Following the completion of the acquisition, the director now directly owns 1,100,730 shares of the company’s stock, valued at approximately $22,785,111. The disclosure for this purchase can be found here. Insiders own 2.90% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.